Combined treatment of gemcitabine with indole-3-carbinol or metformin on drug efficacy in pancreatic cancer cell lines: The role of human equilibrative nucleoside transporters
Journal Title: Journal of Cancer Research & Therapy - Year 2018, Vol 6, Issue 2
Abstract
Pancreatic cancer is one of the most lethal carcinomas in the United States. In accord with the American Cancer Society pancreatic cancer is anticipated to move from the third to the second leading cause of deaths in the United States by 2020. Although the standard treatment for advanced pancreatic cancer is gemcitabine (GEM), the response rate is less than 20%. Chemoresistance is a hallmark of this cancer, and modulation of drug transporters expression has been shown to increase cancer drug efficacy. Studies have shown that human equilibrative nucleoside transporters (hENTs) expression patterns may predict GEM treatment efficacy. This study investigated whether or not GEM in combination with metformin (MET) or indole-3-carbinol (I3C) increases cytotoxicity and modulates hENT1 and hENT4. Pancreatic cancer cells from males and females were treated for 24 or 72h with GEM and/or MET or I3C. Cell viability, drug interactions, and protein and mRNA expression levels of hENTs were assessed. Treatment with GEM and/or MET or I3C showed cell line specific reductions in pancreatic cancer cell proliferation, and modulation of hENT1 and hENT4 expression. Response to GEM and MET/I3C may be dependent upon the genetic profile of the tumor and the level of expression of a specific transporter. The sensitivity of GEM could depend on the method of treatment, whether cells were pre-treated with MET or I3C, which studies, including our own, have showed that pre-treatment with I3C increased upregulation of hENT1 expression in pancreatic cancer cell lines.
Authors and Affiliations
Stancy Joseph, Word B, Lyn-Cook B
Keywords
Related Articles
- EP ID EP529733
- DOI 10.14312/2052-4994.2018-2
- Views 62
- Downloads 0
Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2/II
CIGB-300 is a pro-apoptotic casein kinase 2 inhibitor peptide with potential anticancer action. An open-label and dose scaling Phase I trial was carried out to investigate the peptide tumor uptake, pharmacokinetics, toxi...
HTLV-1 can be involved in acceleration of different nonhematological cancers
In the past two decades it has been found that viral proteins might contribute to activation of numerous pathways involved in different types of cancer. Human T-lymphotropic virus 1 (HTLV-1), well known as a cause of T-c...
Total meso-esophagogastrectomy in surgically resectable Siewert type II-III junctional gastric cancer: Safety and long term oncologic outcome
Aim: To analyze our experience confronting meso-esophagogastric resection (transhiatally extended total gastrectomy en-bloc with its inviolate primitive dorsal and ventral mesenterium) to less radical planes of surgery (...
High grade endometrial cancer: A prospective cohort study of the outcome of 120 patients after primary surgery
Objective: The purpose of this study was to assess survival and recurrence site and rate in patients with histological high grade endometrial cancer (grade 3 endometrioid and non endometrioid carcinoma) treated with stag...
Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay
In order to analyze detailed anthropometric characterisation for risk of breast cancer (BC) in premenopausal Uruguayan women, a case-control study was carried out at the Pereira Rossell Women’s Hospital, Montevideo, wher...